Advertisement

Topics

Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria

05:00 EDT 14 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Zavicefta™ Launches Address Urgent Medical Need for New Antibiotics Pfizer Inc. today announced that Zavicefta, a novel combination antibiotic for the treatment of patients with certain confirmed or suspected Gram-negative...

Other Sources for this Article

Pfizer Media:
Allyanna Anglim, 212-733-4945
Allyanna.Anglim@pfizer.com
or
Pfizer E.U. Media:
Lisa O’Neill, +44 7929 339 560
Lisa.O'Neill@pfizer.com
or
Pfizer Investors:
Ryan Crowe, 212-733-8160
Ryan.Crowe@pfizer.com

NEXT ARTICLE

More From BioPortfolio on "Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...